Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with Vigil vs. less than 2 years (19 months) for placebo (HR=0.23; p=0.008)7-year ...

In this systematic review and meta-analysis, researchers examined outcomes among advanced ovarian cancer patients who ...

A new clinical study published in the International Journal of Gynecological Cancer reports encouraging results for women ...

Suvemcitug combined with chemotherapy significantly improved PFS and OS in platinum-resistant recurrent ovarian cancer, nearly doubling median PFS and extending median OS. The trial demonstrated ...

Sevabertinib, targeting HER2 and EGFR mutations, received FDA breakthrough designation for HER2+ NSCLC, showing a 59% overall ...

Enhanced chemosensitivity: Laboratory data suggest PRP makes resistant pancreatic tumor cells more responsive to standard chemotherapies and alters the tumor microenvironment — including reduced ...

UT biochemistry major Milit Patel collaborated with researchers at Memorial Sloan Kettering Cancer Center on research published in a top cancer journal.

The American Cancer Society today released its annual “Cancer Statistics, 2026” and “Cancer Facts & Figures 2026” report — the first national snapshot of this year’s cancer trends. Experts from City ...

In this analysis of the phase 3 ALLTO trial, researchers explored 10-year outcomes of HR+, HER2+ early breast cancer patients who received either an aromatase inhibitor or a selective estrogen ...

The Signatera assay showed positive correlations between ctDNA presence and cancer recurrence, suggesting its potential for ...

Women’s health exits topped $100 billion across 276 deals. New AOA Dx data show the category delivers healthcare M&A and ...

The FDA is expected to decide on treatments for allergic fungal rhinosinusitis, bipolar I disorder, Hunter syndrome, Leber hereditary optic neuropathy, ovarian cancer, and schizophrenia.